Soft tissue sarcomas & GIST

Soft tissue sarcomas (STS) are a rare and heterogeneous disease sharing mesenchymal origin. While classification of different STS subtypes has generated insight into their molecular pathogenesis, treatment response, and prognosis, oncological management still poses major clinical challenges. Despite considerable evolution in definition of optimal treatment strategies over the past decade there is a critical need of new and less toxic therapeutic approaches for the treatment of metastatic sarcoma. This review covers the latest clinical study highlights for soft tissue sarcomas and gastroinestinal stromal tumours (GIST) presented at ASCO 2016, demonstrating a constant progress from conventional chemotherapy to histology-tailored therapy as well as immunotherapy approaches.